Skip to main content

Advertisement

Table 3 Linear logistic regression models of time weighted AUC0–24 h by adverse event (N = 1465 participants)

From: Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

Adverse event Estimate (standard error) Odds ratio (95% CI) P value
Insomnia/sleep disorders − 0.0919 (0.0479) 0.912 (0.830, 1.002) 0.0549
Serious adverse events 0.0470 (0.0285) 1.048 (0.991, 1.108) 0.0989
Psychotic symptoms 0.2671 (0.1959) 1.306 (0.890, 1.917) 0.1728
Muscle spasm 0.1047 (0.0810) 1.110 (0.947, 1.301) 0.1963
Anxiety 0.0611 (0.0475) 1.063 (0.968, 1.167) 0.1987
Rash/dermatitis/urticaria − 0.0363 (0.0466) 0.964 (0.880, 1.057) 0.4356
Diarrhea 0.0267 (0.0441) 1.027 (0.942, 1.120) 0.5444
Falls and injuries − 0.0171 (0.0353) 0.983 (0.917, 1.053) 0.6274
Pain in the extremity 0.0270 (0.0733) 1.027 (0.890, 1.186) 0.7128
Syncope-like (with loss of consciousness) 0.0188 (0.0557) 1.019 (0.914, 1.137) 0.7355
Rash event of clinical interest 0.0176 (0.0585) 1.018 (0.907, 1.141) 0.7639
Weight decreased − 0.0106 (0.0483) 0.989 (0.900, 1.088) 0.8260
Suicidal ideation − 0.0041 (0.0498) 0.996 (0.903, 1.098) 0.9342
  1. AUC0-24 h, area under the concentration time curve within a 24-h dosing interval at steady state